This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Humacyte, Inc. (HUMA) reachead $5.17 at the closing of the latest trading day, reflecting a -1.34% change compared to its last close.
Should You Buy Humacyte (HUMA) Ahead of Earnings?
by Zacks Equity Research
Humacyte (HUMA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
by Zacks Equity Research
Humacyte (HUMA) gains 16% as the FDA accepts its BLA for the HAV bioengineered tissue to treat vascular trauma under Priority Review. A final decision is expected in August 2024.
Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 0% and 68.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 0% and 14.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aeglea (AGLE) delivered earnings and revenue surprises of -5.26% and 16.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 1,860% and 51.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?
by Zacks Equity Research
Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Humacyte (HUMA) Completes Enrollment in HAV Technology Study
by Zacks Equity Research
Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in hemodialysis patients.
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 12.50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.90% and 131.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 0.65% and 8.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -19.05% and 88.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Prometheus Biosciences, Inc. (RXDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -1.12% and 26.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 42.31% and 11.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See an 85% Upside in Humacyte, Inc. (HUMA): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at an 84.8% upside potential for Humacyte, Inc. (HUMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Henry Schein (HSIC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Henry Schein (HSIC) and Humacyte, Inc. (HUMA) have performed compared to their sector so far this year.